Genelux (GNLX) EBT Margin (2022 - 2024)

Genelux (GNLX) recorded quarterly EBT Margin of 98125.0% in Q1 2024, down 1642.71% quarter-over-quarter from 5630.59% in Q1 2023, and down 9249441.0% on a YoY basis from N/an in Q2 2023.

Genelux (GNLX) EBT Margin (2022 - 2024) Analysis & Trends

Genelux's EBT Margin history runs 3 years deep, the most recent figure standing at 98125.0% for Q1 2024.

  • In Q1 2024, EBT Margin fell 9249441.0% year-over-year to 98125.0%; the TTM figure through Dec 2024 stood at 385562.5% (down 36961956.0% YoY), while the FY2025 annual figure was 406287.5%, down 1883750.0% from the prior year.
  • EBT Margin was 98125.0% for Q1 2024 at Genelux, down from 5630.59% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 54.63% in Q3 2022 to a low of 98125.0% in Q1 2024.
  • Historically, EBT Margin has averaged 25917.17% across 3 years, with a median of 2799.16% in 2023.
  • Biggest YoY gain for EBT Margin was 9249441 bps in 2024; the steepest drop was 9249441 bps in 2024.
  • A 3-year view of EBT Margin shows it stood at 32.27% in 2022, then sank by 17548 bps to 5630.59% in 2023, then slumped by 1643 bps to 98125.0% in 2024.
  • The last three EBT Margin figures came in at 98125.0% (Q1 2024), 5630.59% (Q1 2023), and 32.27% (Q4 2022), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBT Margin (Qtr)
1 Alterity Therapeutics 925,601.88 Bn 925,601.85 Bn - -
2 Belite Bio 58,560.00 Bn 58,560.00 Bn - -
3 Quantum Biopharma 17,284.41 Bn 17,284.40 Bn - -
4 Legend Biotech 2,809.00 Bn 2,808.71 Bn 242.10 Mn 6.40%
5 Evaxion A 1,334.43 Bn 1,334.42 Bn - -
6 Akari Therapeutics 1,312.27 Bn 1,312.26 Bn - -
7 Psyence Biomedical 212.16 Bn 212.16 Bn - -
8 Vertex Pharmaceuticals 114.83 Bn 107.58 Bn 2.59 Bn 41.95%
9 Abivax 91.96 Bn 91.96 Bn - -
10 Genelux 129.36 Mn 129.36 Mn - -

Historic Data

Download Data
DateValue
Mar 31, 2024 -98,125.00%
Mar 31, 2023 -5,630.59%
Dec 31, 2022 32.27%
Sep 30, 2022 54.63%